Home / Market News / $TRLV
benzinga Corporate Catalyst Impact 92/100 ● positive

Trulieve Cannabis Q2 Adj. EPS $0.11 Beats $0.06 Estimate, Sales $271.000M Beat $268.494M Estimate

Aug 7, 2026, 1:04 PM UTC · Primary ticker $TRLV

Trulieve Cannabis reported Q2 adjusted EPS of $0.11, significantly beating analyst estimates of $0.06, and sales of $271 million, also surpassing the $268.494 million estimate. This strong earnings beat, despite a year-over-year sales decrease, suggests improved operational efficiency and profitability for the company.

Trulieve Cannabis (TRLV) announced Q2 adjusted EPS of $0.11, which was an 83.33% beat over the analyst consensus of $0.06, and a substantial 375% increase from a loss in the prior year. Sales of $271 million also slightly beat estimates, although they represent a 10.26% decrease year-over-year. This filing is significant because the substantial EPS beat indicates improved profitability and operational management, which is a positive signal for investors. While the sales decline year-over-year could be a concern, the beat against current estimates and the strong EPS growth suggest the company is navigating market conditions effectively. This could lead to short-term positive price movement for TRLV as investors react to the better-than-expected financial performance, potentially attracting new investment and improving market sentiment for the stock.

$TRLV positive Strong earnings and sales beat
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.